{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"retatrutide-neuropathy","title":"Retatrutide for Neuropathy: Evidence Review","body":"## What's breaking down\n\nNeuropathy involves degeneration of peripheral nerves. Layers include metabolic stress from high blood sugar or excess weight, chronic low-grade inflammation, and impaired nerve repair signals. In diabetic cases, prolonged hyperglycemia damages small blood vessels that supply nerves, leading to sensory loss, pain, or tingling. Excess body weight adds indirect pressure through poorer circulation and higher systemic load on tissues. Repair pathways lag behind breakdown when metabolic control stays poor. Retatrutide is studied mainly for weight and glucose effects, not as a direct nerve regenerator.\n\n## Why Retatrutide might help you\n\n1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. This mechanical burden can worsen nerve compression or circulation issues in neuropathy.\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf metabolic load contributes to your nerve symptoms through added tissue stress, reduced body weight could ease overall demand on nerves. This is an indirect pathway focused on lowering the breakdown rate rather than accelerating repair signals.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\n## What the evidence actually shows\n\nNo human trials test retatrutide specifically for neuropathy treatment (preclinical|mechanistic). Phase 2 and 3 trials (human) report dysesthesia as an adverse event in 2-20.9% of participants at higher doses, described as tingling, burning, or abnormal sensations (human). These events were generally mild and often resolved (human). Weight loss reached up to 16.9-28% in trials with type 2 diabetes or obesity (human). No data link the drug to improved nerve conduction or reduced neuropathic pain scores.\n\nAnimal studies on triple agonists show metabolic improvements but no direct neuropathy reversal data for retatrutide (preclinical). Reddit threads describe users developing or experiencing worsened skin sensitivity and nerve-like pain while on retatrutide (anecdotal). X posts mirror reports of transient tingling without clear resolution patterns (anecdotal).\n\n## What scientists say\n\nResearchers note dysesthesia as a dose-dependent signal possibly tied to the glucagon receptor component or rapid metabolic shifts, not permanent nerve damage (mechanistic|human). Publications emphasize monitoring for nutrient deficiencies during weight loss that could mimic or worsen nerve symptoms (human). No statements claim retatrutide repairs nerves; focus remains on glycemic and weight outcomes (human).\n\n## What people say on Reddit\n\nUsers in r/Retatrutide report new or intensified tingling, hypersensitivity, or dysesthesia after starting the compound, with some linking it to dose increases (anecdotal). Others note symptoms fading after stabilization or nutritional support (anecdotal). Threads question whether pre-existing neuropathy worsens or if rapid weight loss plays a role (anecdotal).\n\n## What people say on X\n\nPosts describe similar transient skin sensations or nerve discomfort during retatrutide use, often in context of high-dose phases (anecdotal). Few detail long-term outcomes or comparisons to baseline neuropathy (anecdotal).\n\n## What we do not know\n\nDirect effects on nerve regeneration or diabetic neuropathy progression remain unstudied in humans (speculative). Whether weight loss from retatrutide translates to measurable nerve function gains is unknown (speculative). Long-term safety beyond 68 weeks for neurological outcomes lacks data (speculative).\n\n## Safety and limits\n\nDysesthesia appears in trial safety data at rates higher than placebo (human). Most cases were mild; some required evaluation for other causes like vitamin deficiencies (human). Retatrutide remains investigational with no approved indication for neuropathy (human). Individual responses vary; pre-existing nerve conditions warrant separate assessment outside weight-loss contexts.\n\nRetatrutide targets metabolic load reduction. Neuropathy involves multiple degeneration layers where this may intersect indirectly at best. Evidence centers on side-effect profiles rather than therapeutic nerve repair.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials test retatrutide for neuropathy treatment.","section":"What the evidence actually shows","tier":"human","source_ids":["s9","s11"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 2/3 trials report dysesthesia in 2-20.9% at higher doses.","section":"What the evidence actually shows","tier":"human","source_ids":["s2","s4","s5","s17"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Weight loss in trials reached 16.9-28%.","section":"What the evidence actually shows","tier":"human","source_ids":["s9","s11","s23"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Dysesthesia linked possibly to glucagon receptor or metabolic shifts.","section":"What scientists say","tier":"mechanistic","source_ids":["s2","s4","s8"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report new tingling or hypersensitivity on retatrutide.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s0","s18","s19","s20"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"X posts describe transient nerve-like sensations during use.","section":"What people say on X","tier":"anecdotal","source_ids":["s2"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1iijrti/neuropathy/","title":"Neuropathy?","quote":"I developed bad neuropathy or dysesthesia.","summary":"User report of neuropathy symptoms on retatrutide.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"7cf2923667c107e4087be796281958aa6071a584b9a2b7b628689f7c3dda13bd"},{"id":"s2","type":"other","url":"https://www.retaweightloss.com/article/dysesthesia-from-retatrutide-the-side-effect-nobody-talks-about","title":"Retatrutide Dysesthesia","quote":"dysesthesia affecting 20.9% of patients at the highest dose","summary":"Details trial dysesthesia rates and possible glucagon link.","claim_ids":["c2","c6","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"verified","prev":"7cf2923667c107e4087be796281958aa6071a584b9a2b7b628689f7c3dda13bd","hash":"10ded82969ddd82b976abec8cce7eb83a79c6432c1df8c64a4399c502e369a21"},{"id":"s4","type":"other","url":"https://trytrimi.com/blog/retatrutide-dysesthesia","title":"Retatrutide Dysesthesia","quote":"Incidence of dysesthesia... 20.9%... at 12mg","summary":"Safety data and management notes.","claim_ids":["c2","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"10ded82969ddd82b976abec8cce7eb83a79c6432c1df8c64a4399c502e369a21","hash":"1aad5bc5d18934ea30e572d6ac1b355f485cdb1aa574794e4bffc00d759f8212"},{"id":"s5","type":"other","url":"https://retatrutidepen.co.uk/retatrutide-dysesthesia.html","title":"Managing Tingling...","quote":"dysesthesia as a safety signal in 2-5%... TRIUMPH-4","summary":"Trial findings on dysesthesia.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"1aad5bc5d18934ea30e572d6ac1b355f485cdb1aa574794e4bffc00d759f8212","hash":"9c8e6d1ced96b359252dbd72dec3d668b816a37d6283f55ca7fc7ad9768fd941"},{"id":"s8","type":"other","url":"https://drsue.ca/2025/10/can-glp-1-medications-cause-funky-skin-sensations-dysesthesia/","title":"Can GLP-1 medications cause funky skin sensations","quote":"Dysesthesia was first noted... in retatrutide","summary":"Discussion of side effect mechanisms.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"9c8e6d1ced96b359252dbd72dec3d668b816a37d6283f55ca7fc7ad9768fd941","hash":"7981c96ef6679311e6158f5ff468c8c707dc5d2056b9c8e94c456ea2574fcd56"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/","title":"Retatrutide—A Game Changer","quote":"Bodyweight decreased... up to 16.94%... 12 mg","summary":"Phase 2 trial weight and HbA1c results.","claim_ids":["c1","c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"7981c96ef6679311e6158f5ff468c8c707dc5d2056b9c8e94c456ea2574fcd56","hash":"8ce50033d8476867b1402b78b577494f1c12830bbfb2799e6ca82d887d2d9142"},{"id":"s11","type":"other","url":"https://diabetes.org/newsroom/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium","title":"ADA highlights retatrutide results","quote":"average weight reduction for the 12 mg group was 16.9%","summary":"Trial outcomes in T2D.","claim_ids":["c1","c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"verified","prev":"8ce50033d8476867b1402b78b577494f1c12830bbfb2799e6ca82d887d2d9142","hash":"781674cc9c1c18acb3c9b6ae8162f203f4fcf01663432ca4047f97a617136519"},{"id":"s17","type":"news","url":"https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html","title":"Lilly's triple agonist... Phase 3","quote":"Incidence of dysesthesia occurred in 4.5%, 2.3% and 4.4%","summary":"Phase 3 dysesthesia rates.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"verified","prev":"781674cc9c1c18acb3c9b6ae8162f203f4fcf01663432ca4047f97a617136519","hash":"9b79d6970a7a33621fb79197aa3a7ecc11f14990f108872e1756b603334bfcfa"},{"id":"s18","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1iijrti/neuropathy/","title":"Neuropathy?","quote":"Taking Reta going on 6 weeks. Down 35","summary":"User neuropathy experience.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"9b79d6970a7a33621fb79197aa3a7ecc11f14990f108872e1756b603334bfcfa","hash":"708f5fe5177fce61ac48d86f757e243e988b92ca9c460dfad67fdf3bf499e9b5"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/RetatrutideTrial/comments/1kia254/anyone_found_relief_from_skin_sensitivity_on/","title":"Anyone Found Relief from Skin Sensitivity","quote":"I dealt with this immediately... nerve pain","summary":"Skin sensitivity reports.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"708f5fe5177fce61ac48d86f757e243e988b92ca9c460dfad67fdf3bf499e9b5","hash":"06090cc1b8f026f73060aefb86cbba2cccfd8097da83b2d15b91934fa080d3c6"},{"id":"s20","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1s7s46m/peripheral_neuropathy/","title":"Peripheral Neuropathy","quote":"had a question if anyone has experienced","summary":"Peripheral neuropathy discussion.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"06090cc1b8f026f73060aefb86cbba2cccfd8097da83b2d15b91934fa080d3c6","hash":"0623e07a1d401ab656fb98257b1c919e7337daccb55d8ea4bc40d5d1160b2a9d"},{"id":"s23","type":"news","url":"https://www.uchealth.org/today/retatrutide-for-weight-loss/","title":"Retatrutide for weight loss","quote":"lost about 30% of their body weight","summary":"Weight loss results.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"0623e07a1d401ab656fb98257b1c919e7337daccb55d8ea4bc40d5d1160b2a9d","hash":"c96055b30d901bffa3d71e1523b8d35acb307e5aae60cc637bd7f88810f5f07c"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:56:11.776Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Retatrutide for Neuropathy: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves degeneration of peripheral nerves. Layers include metabolic stress from high blood sugar or excess weight, chronic low-grade inflammation, and impaired nerve repair signals. In diabetic cases, prolonged hyperglycemia damages small blood vessels that supply nerves, leading to sensory loss, pain, or tingling. Excess body weight adds indirect pressure through poorer circulation and higher systemic load on tissues. Repair pathways lag behind breakdown when metabolic control stays poor. Retatrutide is studied mainly for weight and glucose effects, not as a direct nerve regenerator.\n\n## Why Retatrutide might help you\n\n1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. This mechanical burden can worsen nerve compression or circulation issues in neuropathy.\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf metabolic load contributes to your nerve symptoms through added tissue stress, reduced body weight could ease overall demand on nerves. This is an indirect pathway focused on lowering the breakdown rate rather than accelerating repair signals.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\n## What the evidence actually shows\n\nNo human trials test retatrutide specifically for neuropathy treatment (preclinical|mechanistic). Phase 2 and 3 trials (human) report dysesthesia as an adverse event in 2-20.9% of participants at higher doses, described as tingling, burning, or abnormal sensations (human). These events were generally mild and often resolved (human). Weight loss reached up to 16.9-28% in trials with type 2 diabetes or obesity (human). No data link the drug to improved nerve conduction or reduced neuropathic pain scores.\n\nAnimal studies on triple agonists show metabolic improvements but no direct neuropathy reversal data for retatrutide (preclinical). Reddit threads describe users developing or experiencing worsened skin sensitivity and nerve-like pain while on retatrutide (anecdotal). X posts mirror reports of transient tingling without clear resolution patterns (anecdotal).\n\n## What scientists say\n\nResearchers note dysesthesia as a dose-dependent signal possibly tied to the glucagon receptor component or rapid metabolic shifts, not permanent nerve damage (mechanistic|human). Publications emphasize monitoring for nutrient deficiencies during weight loss that could mimic or worsen nerve symptoms (human). No statements claim retatrutide repairs nerves; focus remains on glycemic and weight outcomes (human).\n\n## What people say on Reddit\n\nUsers in r/Retatrutide report new or intensified tingling, hypersensitivity, or dysesthesia after starting the compound, with some linking it to dose increases (anecdotal). Others note symptoms fading after stabilization or nutritional support (anecdotal). Threads question whether pre-existing neuropathy worsens or if rapid weight loss plays a role (anecdotal).\n\n## What people say on X\n\nPosts describe similar transient skin sensations or nerve discomfort during retatrutide use, often in context of high-dose phases (anecdotal). Few detail long-term outcomes or comparisons to baseline neuropathy (anecdotal).\n\n## What we do not know\n\nDirect effects on nerve regeneration or diabetic neuropathy progression remain unstudied in humans (speculative). Whether weight loss from retatrutide translates to measurable nerve function gains is unknown (speculative). Long-term safety beyond 68 weeks for neurological outcomes lacks data (speculative).\n\n## Safety and limits\n\nDysesthesia appears in trial safety data at rates higher than placebo (human). Most cases were mild; some required evaluation for other causes like vitamin deficiencies (human). Retatrutide remains investigational with no approved indication for neuropathy (human). Individual responses vary; pre-existing nerve conditions warrant separate assessment outside weight-loss contexts.\n\nRetatrutide targets metabolic load reduction. Neuropathy involves multiple degeneration layers where this may intersect indirectly at best. Evidence centers on side-effect profiles rather than therapeutic nerve repair.","claims":[{"id":"c1","text":"No human trials test retatrutide for neuropathy treatment.","section":"What the evidence actually shows","tier":"human","source_ids":["s9","s11"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 2/3 trials report dysesthesia in 2-20.9% at higher doses.","section":"What the evidence actually shows","tier":"human","source_ids":["s2","s4","s5","s17"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Weight loss in trials reached 16.9-28%.","section":"What the evidence actually shows","tier":"human","source_ids":["s9","s11","s23"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Dysesthesia linked possibly to glucagon receptor or metabolic shifts.","section":"What scientists say","tier":"mechanistic","source_ids":["s2","s4","s8"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report new tingling or hypersensitivity on retatrutide.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s0","s18","s19","s20"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"X posts describe transient nerve-like sensations during use.","section":"What people say on X","tier":"anecdotal","source_ids":["s2"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1iijrti/neuropathy/","title":"Neuropathy?","quote":"I developed bad neuropathy or dysesthesia.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"other","url":"https://www.retaweightloss.com/article/dysesthesia-from-retatrutide-the-side-effect-nobody-talks-about","title":"Retatrutide Dysesthesia","quote":"dysesthesia affecting 20.9% of patients at the highest dose","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"other","url":"https://trytrimi.com/blog/retatrutide-dysesthesia","title":"Retatrutide Dysesthesia","quote":"Incidence of dysesthesia... 20.9%... at 12mg","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"other","url":"https://retatrutidepen.co.uk/retatrutide-dysesthesia.html","title":"Managing Tingling...","quote":"dysesthesia as a safety signal in 2-5%... TRIUMPH-4","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"other","url":"https://drsue.ca/2025/10/can-glp-1-medications-cause-funky-skin-sensations-dysesthesia/","title":"Can GLP-1 medications cause funky skin sensations","quote":"Dysesthesia was first noted... in retatrutide","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/","title":"Retatrutide—A Game Changer","quote":"Bodyweight decreased... up to 16.94%... 12 mg","link_status":"ok","quote_status":"unverified"},{"id":"s11","type":"other","url":"https://diabetes.org/newsroom/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium","title":"ADA highlights retatrutide results","quote":"average weight reduction for the 12 mg group was 16.9%","link_status":"ok","quote_status":"verified"},{"id":"s17","type":"news","url":"https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html","title":"Lilly's triple agonist... Phase 3","quote":"Incidence of dysesthesia occurred in 4.5%, 2.3% and 4.4%","link_status":"ok","quote_status":"verified"},{"id":"s18","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1iijrti/neuropathy/","title":"Neuropathy?","quote":"Taking Reta going on 6 weeks. Down 35","link_status":"ok","quote_status":"unverified"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/RetatrutideTrial/comments/1kia254/anyone_found_relief_from_skin_sensitivity_on/","title":"Anyone Found Relief from Skin Sensitivity","quote":"I dealt with this immediately... nerve pain","link_status":"ok","quote_status":"unverified"},{"id":"s20","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1s7s46m/peripheral_neuropathy/","title":"Peripheral Neuropathy","quote":"had a question if anyone has experienced","link_status":"ok","quote_status":"unverified"},{"id":"s23","type":"news","url":"https://www.uchealth.org/today/retatrutide-for-weight-loss/","title":"Retatrutide for weight loss","quote":"lost about 30% of their body weight","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":15628,"tokens_out":3265,"cost":0.0276975,"prev_hash":"genesis","hash":"164f593625d528510a15c72740ad7a293dbdb6a682466e22d360775d38b45b4a"}],"provenance":[{"ts":"2026-06-30T00:56:11.776Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Neuropathy\nSlug: retatrutide-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[","response":"{\"slug\":\"retatrutide-neuropathy\",\"title\":\"Retatrutide for Neuropathy: Evidence Review\",\"body\":\"## What's breaking down\\n\\nNeuropathy involves degeneration of peripheral nerves. Layers include metabolic stress from high blood sugar or excess weight, chronic low-grade inflammation, and impaired nerve repair signals. In diabetic cases, prolonged hyperglycemia damages small blood vessels that supply nerves, leading to sensory loss, pain, or tingling. Excess body weight adds indirect pressure through poorer circulation and higher systemic load on tissues. Repair pathways lag behind breakdown when metabolic control stays poor. Retatrutide is studied mainly for weight and glucose effects, not as a direct nerve regenerator.\\n\\n## Why Retatrutide might help you\\n\\n1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. This mechanical burden can worsen nerve compression or circulation issues in neuropathy.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nIf metabolic load contributes to your nerve symptoms through added tissue stress, reduced body weight could ease overall demand on nerves. This is an indirect pathway focused on lowering the breakdown rate rather than accelerating repair signals.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Retatrutide** → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nNo human trials test retatrutide specifically for neuropathy treatment (preclinical|mechanistic). Phase 2 and 3 trials (human) report dysesthesia as an adverse event in 2-20.9% of partic","tokens_in":15628,"tokens_out":3265,"cost":0,"prev":"genesis","hash":"7dc327c29408e3954a7c7eaff16d818a0059e2fbaffd65f86ff5522b0c238a98"},{"ts":"2026-07-17T02:41:18.907Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-neuropathy","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7dc327c29408e3954a7c7eaff16d818a0059e2fbaffd65f86ff5522b0c238a98","hash":"679fb555d1846bca253dd2590e2f490b3a0a4e76657e674173c27485ca1f2647"}],"energy":{"passes":2,"tokens_in":15628,"tokens_out":3265,"tokens_total":18893,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"679fb555d1846bca253dd2590e2f490b3a0a4e76657e674173c27485ca1f2647"},"posted_at":"2026-06-29T21:33:00.845Z","created_at":"2026-06-29T21:33:00.845Z","updated_at":"2026-07-17T02:41:18.907Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-neuropathy","json":"https://miscsubjects.com/api/articles/retatrutide-neuropathy","bundle":"https://miscsubjects.com/api/articles/retatrutide-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":12,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-neuropathy","json":"/api/articles/retatrutide-neuropathy","markdown":"/api/articles/retatrutide-neuropathy/bundle?format=markdown","skill":"/api/articles/retatrutide-neuropathy/skill","topology":"/api/articles/retatrutide-neuropathy/topology","versions":"/api/articles/retatrutide-neuropathy/revisions","invocations":"/api/articles/retatrutide-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"90b36c05dfcc283ef1fe9989a5c66c034207a804480ed2f135c0b763296036e0","object":{"object_type":"article-object","identity":{"id":"article:retatrutide-neuropathy","slug":"retatrutide-neuropathy","title":"Retatrutide for Neuropathy: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/retatrutide-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/retatrutide-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: retatrutide-neuropathy\ndescription: Apply the Retatrutide for Neuropathy: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Retatrutide for Neuropathy: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/retatrutide-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/retatrutide-neuropathy.\n- Read claims and relationships at /api/articles/retatrutide-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Neuropathy involves degeneration of peripheral nerves. Layers include metabolic stress from high blood sugar or excess weight, chronic low-grade inflammation, and impaired nerve repair signals. In diabetic cases, prolon\n\n## Representations\n\n- Human: /a/retatrutide-neuropathy\n- JSON: /api/articles/retatrutide-neuropathy\n- Relationships: /api/articles/retatrutide-neuropathy/topology\n- History: /api/articles/retatrutide-neuropathy/revisions\n"},"json":{"route":"/api/articles/retatrutide-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/retatrutide-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","retatrutide","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/retatrutide-neuropathy/invocations?status=success","failure_events":"/api/articles/retatrutide-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"retatrutide-neuropathy","title":"Retatrutide for Neuropathy: Evidence Review","body":"## What's breaking down\n\nNeuropathy involves degeneration of peripheral nerves. Layers include metabolic stress from high blood sugar or excess weight, chronic low-grade inflammation, and impaired nerve repair signals. In diabetic cases, prolonged hyperglycemia damages small blood vessels that supply nerves, leading to sensory loss, pain, or tingling. Excess body weight adds indirect pressure through poorer circulation and higher systemic load on tissues. Repair pathways lag behind breakdown when metabolic control stays poor. Retatrutide is studied mainly for weight and glucose effects, not as a direct nerve regenerator.\n\n## Why Retatrutide might help you\n\n1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. This mechanical burden can worsen nerve compression or circulation issues in neuropathy.\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf metabolic load contributes to your nerve symptoms through added tissue stress, reduced body weight could ease overall demand on nerves. This is an indirect pathway focused on lowering the breakdown rate rather than accelerating repair signals.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\n## What the evidence actually shows\n\nNo human trials test retatrutide specifically for neuropathy treatment (preclinical|mechanistic). Phase 2 and 3 trials (human) report dysesthesia as an adverse event in 2-20.9% of participants at higher doses, described as tingling, burning, or abnormal sensations (human). These events were generally mild and often resolved (human). Weight loss reached up to 16.9-28% in trials with type 2 diabetes or obesity (human). No data link the drug to improved nerve conduction or reduced neuropathic pain scores.\n\nAnimal studies on triple agonists show metabolic improvements but no direct neuropathy reversal data for retatrutide (preclinical). Reddit threads describe users developing or experiencing worsened skin sensitivity and nerve-like pain while on retatrutide (anecdotal). X posts mirror reports of transient tingling without clear resolution patterns (anecdotal).\n\n## What scientists say\n\nResearchers note dysesthesia as a dose-dependent signal possibly tied to the glucagon receptor component or rapid metabolic shifts, not permanent nerve damage (mechanistic|human). Publications emphasize monitoring for nutrient deficiencies during weight loss that could mimic or worsen nerve symptoms (human). No statements claim retatrutide repairs nerves; focus remains on glycemic and weight outcomes (human).\n\n## What people say on Reddit\n\nUsers in r/Retatrutide report new or intensified tingling, hypersensitivity, or dysesthesia after starting the compound, with some linking it to dose increases (anecdotal). Others note symptoms fading after stabilization or nutritional support (anecdotal). Threads question whether pre-existing neuropathy worsens or if rapid weight loss plays a role (anecdotal).\n\n## What people say on X\n\nPosts describe similar transient skin sensations or nerve discomfort during retatrutide use, often in context of high-dose phases (anecdotal). Few detail long-term outcomes or comparisons to baseline neuropathy (anecdotal).\n\n## What we do not know\n\nDirect effects on nerve regeneration or diabetic neuropathy progression remain unstudied in humans (speculative). Whether weight loss from retatrutide translates to measurable nerve function gains is unknown (speculative). Long-term safety beyond 68 weeks for neurological outcomes lacks data (speculative).\n\n## Safety and limits\n\nDysesthesia appears in trial safety data at rates higher than placebo (human). Most cases were mild; some required evaluation for other causes like vitamin deficiencies (human). Retatrutide remains investigational with no approved indication for neuropathy (human). Individual responses vary; pre-existing nerve conditions warrant separate assessment outside weight-loss contexts.\n\nRetatrutide targets metabolic load reduction. Neuropathy involves multiple degeneration layers where this may intersect indirectly at best. Evidence centers on side-effect profiles rather than therapeutic nerve repair.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials test retatrutide for neuropathy treatment.","section":"What the evidence actually shows","tier":"human","source_ids":["s9","s11"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 2/3 trials report dysesthesia in 2-20.9% at higher doses.","section":"What the evidence actually shows","tier":"human","source_ids":["s2","s4","s5","s17"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Weight loss in trials reached 16.9-28%.","section":"What the evidence actually shows","tier":"human","source_ids":["s9","s11","s23"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Dysesthesia linked possibly to glucagon receptor or metabolic shifts.","section":"What scientists say","tier":"mechanistic","source_ids":["s2","s4","s8"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report new tingling or hypersensitivity on retatrutide.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s0","s18","s19","s20"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"X posts describe transient nerve-like sensations during use.","section":"What people say on X","tier":"anecdotal","source_ids":["s2"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1iijrti/neuropathy/","title":"Neuropathy?","quote":"I developed bad neuropathy or dysesthesia.","summary":"User report of neuropathy symptoms on retatrutide.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"7cf2923667c107e4087be796281958aa6071a584b9a2b7b628689f7c3dda13bd"},{"id":"s2","type":"other","url":"https://www.retaweightloss.com/article/dysesthesia-from-retatrutide-the-side-effect-nobody-talks-about","title":"Retatrutide Dysesthesia","quote":"dysesthesia affecting 20.9% of patients at the highest dose","summary":"Details trial dysesthesia rates and possible glucagon link.","claim_ids":["c2","c6","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"verified","prev":"7cf2923667c107e4087be796281958aa6071a584b9a2b7b628689f7c3dda13bd","hash":"10ded82969ddd82b976abec8cce7eb83a79c6432c1df8c64a4399c502e369a21"},{"id":"s4","type":"other","url":"https://trytrimi.com/blog/retatrutide-dysesthesia","title":"Retatrutide Dysesthesia","quote":"Incidence of dysesthesia... 20.9%... at 12mg","summary":"Safety data and management notes.","claim_ids":["c2","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"10ded82969ddd82b976abec8cce7eb83a79c6432c1df8c64a4399c502e369a21","hash":"1aad5bc5d18934ea30e572d6ac1b355f485cdb1aa574794e4bffc00d759f8212"},{"id":"s5","type":"other","url":"https://retatrutidepen.co.uk/retatrutide-dysesthesia.html","title":"Managing Tingling...","quote":"dysesthesia as a safety signal in 2-5%... TRIUMPH-4","summary":"Trial findings on dysesthesia.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"1aad5bc5d18934ea30e572d6ac1b355f485cdb1aa574794e4bffc00d759f8212","hash":"9c8e6d1ced96b359252dbd72dec3d668b816a37d6283f55ca7fc7ad9768fd941"},{"id":"s8","type":"other","url":"https://drsue.ca/2025/10/can-glp-1-medications-cause-funky-skin-sensations-dysesthesia/","title":"Can GLP-1 medications cause funky skin sensations","quote":"Dysesthesia was first noted... in retatrutide","summary":"Discussion of side effect mechanisms.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"9c8e6d1ced96b359252dbd72dec3d668b816a37d6283f55ca7fc7ad9768fd941","hash":"7981c96ef6679311e6158f5ff468c8c707dc5d2056b9c8e94c456ea2574fcd56"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/","title":"Retatrutide—A Game Changer","quote":"Bodyweight decreased... up to 16.94%... 12 mg","summary":"Phase 2 trial weight and HbA1c results.","claim_ids":["c1","c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"7981c96ef6679311e6158f5ff468c8c707dc5d2056b9c8e94c456ea2574fcd56","hash":"8ce50033d8476867b1402b78b577494f1c12830bbfb2799e6ca82d887d2d9142"},{"id":"s11","type":"other","url":"https://diabetes.org/newsroom/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium","title":"ADA highlights retatrutide results","quote":"average weight reduction for the 12 mg group was 16.9%","summary":"Trial outcomes in T2D.","claim_ids":["c1","c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"verified","prev":"8ce50033d8476867b1402b78b577494f1c12830bbfb2799e6ca82d887d2d9142","hash":"781674cc9c1c18acb3c9b6ae8162f203f4fcf01663432ca4047f97a617136519"},{"id":"s17","type":"news","url":"https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html","title":"Lilly's triple agonist... Phase 3","quote":"Incidence of dysesthesia occurred in 4.5%, 2.3% and 4.4%","summary":"Phase 3 dysesthesia rates.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"verified","prev":"781674cc9c1c18acb3c9b6ae8162f203f4fcf01663432ca4047f97a617136519","hash":"9b79d6970a7a33621fb79197aa3a7ecc11f14990f108872e1756b603334bfcfa"},{"id":"s18","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1iijrti/neuropathy/","title":"Neuropathy?","quote":"Taking Reta going on 6 weeks. Down 35","summary":"User neuropathy experience.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"9b79d6970a7a33621fb79197aa3a7ecc11f14990f108872e1756b603334bfcfa","hash":"708f5fe5177fce61ac48d86f757e243e988b92ca9c460dfad67fdf3bf499e9b5"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/RetatrutideTrial/comments/1kia254/anyone_found_relief_from_skin_sensitivity_on/","title":"Anyone Found Relief from Skin Sensitivity","quote":"I dealt with this immediately... nerve pain","summary":"Skin sensitivity reports.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"708f5fe5177fce61ac48d86f757e243e988b92ca9c460dfad67fdf3bf499e9b5","hash":"06090cc1b8f026f73060aefb86cbba2cccfd8097da83b2d15b91934fa080d3c6"},{"id":"s20","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1s7s46m/peripheral_neuropathy/","title":"Peripheral Neuropathy","quote":"had a question if anyone has experienced","summary":"Peripheral neuropathy discussion.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"06090cc1b8f026f73060aefb86cbba2cccfd8097da83b2d15b91934fa080d3c6","hash":"0623e07a1d401ab656fb98257b1c919e7337daccb55d8ea4bc40d5d1160b2a9d"},{"id":"s23","type":"news","url":"https://www.uchealth.org/today/retatrutide-for-weight-loss/","title":"Retatrutide for weight loss","quote":"lost about 30% of their body weight","summary":"Weight loss results.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:56:10.991Z","link_status":"ok","quote_status":"unverified","prev":"0623e07a1d401ab656fb98257b1c919e7337daccb55d8ea4bc40d5d1160b2a9d","hash":"c96055b30d901bffa3d71e1523b8d35acb307e5aae60cc637bd7f88810f5f07c"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:56:11.776Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Retatrutide for Neuropathy: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves degeneration of peripheral nerves. Layers include metabolic stress from high blood sugar or excess weight, chronic low-grade inflammation, and impaired nerve repair signals. In diabetic cases, prolonged hyperglycemia damages small blood vessels that supply nerves, leading to sensory loss, pain, or tingling. Excess body weight adds indirect pressure through poorer circulation and higher systemic load on tissues. Repair pathways lag behind breakdown when metabolic control stays poor. Retatrutide is studied mainly for weight and glucose effects, not as a direct nerve regenerator.\n\n## Why Retatrutide might help you\n\n1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. This mechanical burden can worsen nerve compression or circulation issues in neuropathy.\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf metabolic load contributes to your nerve symptoms through added tissue stress, reduced body weight could ease overall demand on nerves. This is an indirect pathway focused on lowering the breakdown rate rather than accelerating repair signals.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\n## What the evidence actually shows\n\nNo human trials test retatrutide specifically for neuropathy treatment (preclinical|mechanistic). Phase 2 and 3 trials (human) report dysesthesia as an adverse event in 2-20.9% of participants at higher doses, described as tingling, burning, or abnormal sensations (human). These events were generally mild and often resolved (human). Weight loss reached up to 16.9-28% in trials with type 2 diabetes or obesity (human). No data link the drug to improved nerve conduction or reduced neuropathic pain scores.\n\nAnimal studies on triple agonists show metabolic improvements but no direct neuropathy reversal data for retatrutide (preclinical). Reddit threads describe users developing or experiencing worsened skin sensitivity and nerve-like pain while on retatrutide (anecdotal). X posts mirror reports of transient tingling without clear resolution patterns (anecdotal).\n\n## What scientists say\n\nResearchers note dysesthesia as a dose-dependent signal possibly tied to the glucagon receptor component or rapid metabolic shifts, not permanent nerve damage (mechanistic|human). Publications emphasize monitoring for nutrient deficiencies during weight loss that could mimic or worsen nerve symptoms (human). No statements claim retatrutide repairs nerves; focus remains on glycemic and weight outcomes (human).\n\n## What people say on Reddit\n\nUsers in r/Retatrutide report new or intensified tingling, hypersensitivity, or dysesthesia after starting the compound, with some linking it to dose increases (anecdotal). Others note symptoms fading after stabilization or nutritional support (anecdotal). Threads question whether pre-existing neuropathy worsens or if rapid weight loss plays a role (anecdotal).\n\n## What people say on X\n\nPosts describe similar transient skin sensations or nerve discomfort during retatrutide use, often in context of high-dose phases (anecdotal). Few detail long-term outcomes or comparisons to baseline neuropathy (anecdotal).\n\n## What we do not know\n\nDirect effects on nerve regeneration or diabetic neuropathy progression remain unstudied in humans (speculative). Whether weight loss from retatrutide translates to measurable nerve function gains is unknown (speculative). Long-term safety beyond 68 weeks for neurological outcomes lacks data (speculative).\n\n## Safety and limits\n\nDysesthesia appears in trial safety data at rates higher than placebo (human). Most cases were mild; some required evaluation for other causes like vitamin deficiencies (human). Retatrutide remains investigational with no approved indication for neuropathy (human). Individual responses vary; pre-existing nerve conditions warrant separate assessment outside weight-loss contexts.\n\nRetatrutide targets metabolic load reduction. Neuropathy involves multiple degeneration layers where this may intersect indirectly at best. Evidence centers on side-effect profiles rather than therapeutic nerve repair.","claims":[{"id":"c1","text":"No human trials test retatrutide for neuropathy treatment.","section":"What the evidence actually shows","tier":"human","source_ids":["s9","s11"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 2/3 trials report dysesthesia in 2-20.9% at higher doses.","section":"What the evidence actually shows","tier":"human","source_ids":["s2","s4","s5","s17"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Weight loss in trials reached 16.9-28%.","section":"What the evidence actually shows","tier":"human","source_ids":["s9","s11","s23"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Dysesthesia linked possibly to glucagon receptor or metabolic shifts.","section":"What scientists say","tier":"mechanistic","source_ids":["s2","s4","s8"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report new tingling or hypersensitivity on retatrutide.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s0","s18","s19","s20"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"X posts describe transient nerve-like sensations during use.","section":"What people say on X","tier":"anecdotal","source_ids":["s2"],"source_status":"sourced","why_material":"","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:56:11.381Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1iijrti/neuropathy/","title":"Neuropathy?","quote":"I developed bad neuropathy or dysesthesia.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"other","url":"https://www.retaweightloss.com/article/dysesthesia-from-retatrutide-the-side-effect-nobody-talks-about","title":"Retatrutide Dysesthesia","quote":"dysesthesia affecting 20.9% of patients at the highest dose","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"other","url":"https://trytrimi.com/blog/retatrutide-dysesthesia","title":"Retatrutide Dysesthesia","quote":"Incidence of dysesthesia... 20.9%... at 12mg","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"other","url":"https://retatrutidepen.co.uk/retatrutide-dysesthesia.html","title":"Managing Tingling...","quote":"dysesthesia as a safety signal in 2-5%... TRIUMPH-4","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"other","url":"https://drsue.ca/2025/10/can-glp-1-medications-cause-funky-skin-sensations-dysesthesia/","title":"Can GLP-1 medications cause funky skin sensations","quote":"Dysesthesia was first noted... in retatrutide","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/","title":"Retatrutide—A Game Changer","quote":"Bodyweight decreased... up to 16.94%... 12 mg","link_status":"ok","quote_status":"unverified"},{"id":"s11","type":"other","url":"https://diabetes.org/newsroom/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium","title":"ADA highlights retatrutide results","quote":"average weight reduction for the 12 mg group was 16.9%","link_status":"ok","quote_status":"verified"},{"id":"s17","type":"news","url":"https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html","title":"Lilly's triple agonist... Phase 3","quote":"Incidence of dysesthesia occurred in 4.5%, 2.3% and 4.4%","link_status":"ok","quote_status":"verified"},{"id":"s18","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1iijrti/neuropathy/","title":"Neuropathy?","quote":"Taking Reta going on 6 weeks. Down 35","link_status":"ok","quote_status":"unverified"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/RetatrutideTrial/comments/1kia254/anyone_found_relief_from_skin_sensitivity_on/","title":"Anyone Found Relief from Skin Sensitivity","quote":"I dealt with this immediately... nerve pain","link_status":"ok","quote_status":"unverified"},{"id":"s20","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1s7s46m/peripheral_neuropathy/","title":"Peripheral Neuropathy","quote":"had a question if anyone has experienced","link_status":"ok","quote_status":"unverified"},{"id":"s23","type":"news","url":"https://www.uchealth.org/today/retatrutide-for-weight-loss/","title":"Retatrutide for weight loss","quote":"lost about 30% of their body weight","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":15628,"tokens_out":3265,"cost":0.0276975,"prev_hash":"genesis","hash":"164f593625d528510a15c72740ad7a293dbdb6a682466e22d360775d38b45b4a"}],"provenance":[{"ts":"2026-06-30T00:56:11.776Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Neuropathy\nSlug: retatrutide-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[","response":"{\"slug\":\"retatrutide-neuropathy\",\"title\":\"Retatrutide for Neuropathy: Evidence Review\",\"body\":\"## What's breaking down\\n\\nNeuropathy involves degeneration of peripheral nerves. Layers include metabolic stress from high blood sugar or excess weight, chronic low-grade inflammation, and impaired nerve repair signals. In diabetic cases, prolonged hyperglycemia damages small blood vessels that supply nerves, leading to sensory loss, pain, or tingling. Excess body weight adds indirect pressure through poorer circulation and higher systemic load on tissues. Repair pathways lag behind breakdown when metabolic control stays poor. Retatrutide is studied mainly for weight and glucose effects, not as a direct nerve regenerator.\\n\\n## Why Retatrutide might help you\\n\\n1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. This mechanical burden can worsen nerve compression or circulation issues in neuropathy.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nIf metabolic load contributes to your nerve symptoms through added tissue stress, reduced body weight could ease overall demand on nerves. This is an indirect pathway focused on lowering the breakdown rate rather than accelerating repair signals.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Retatrutide** → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nNo human trials test retatrutide specifically for neuropathy treatment (preclinical|mechanistic). Phase 2 and 3 trials (human) report dysesthesia as an adverse event in 2-20.9% of partic","tokens_in":15628,"tokens_out":3265,"cost":0,"prev":"genesis","hash":"7dc327c29408e3954a7c7eaff16d818a0059e2fbaffd65f86ff5522b0c238a98"},{"ts":"2026-07-17T02:41:18.907Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-neuropathy","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7dc327c29408e3954a7c7eaff16d818a0059e2fbaffd65f86ff5522b0c238a98","hash":"679fb555d1846bca253dd2590e2f490b3a0a4e76657e674173c27485ca1f2647"}],"energy":{"passes":2,"tokens_in":15628,"tokens_out":3265,"tokens_total":18893,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"679fb555d1846bca253dd2590e2f490b3a0a4e76657e674173c27485ca1f2647"},"posted_at":"2026-06-29T21:33:00.845Z","created_at":"2026-06-29T21:33:00.845Z","updated_at":"2026-07-17T02:41:18.907Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-neuropathy","json":"https://miscsubjects.com/api/articles/retatrutide-neuropathy","bundle":"https://miscsubjects.com/api/articles/retatrutide-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":12,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-neuropathy","json":"/api/articles/retatrutide-neuropathy","markdown":"/api/articles/retatrutide-neuropathy/bundle?format=markdown","skill":"/api/articles/retatrutide-neuropathy/skill","topology":"/api/articles/retatrutide-neuropathy/topology","versions":"/api/articles/retatrutide-neuropathy/revisions","invocations":"/api/articles/retatrutide-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"90b36c05dfcc283ef1fe9989a5c66c034207a804480ed2f135c0b763296036e0"}}}